Theralase Technologies–Durchbruch in der Krebsbehandlung (Seite 22)
eröffnet am 15.11.18 17:06:14 von
neuester Beitrag 07.02.24 10:26:16 von
neuester Beitrag 07.02.24 10:26:16 von
Beiträge: 287
ID: 1.292.692
ID: 1.292.692
Aufrufe heute: 0
Gesamt: 24.394
Gesamt: 24.394
Aktive User: 0
ISIN: CA88337V1004 · WKN: A0DLB7
0,1135
EUR
+1,34 %
+0,0015 EUR
Letzter Kurs 22:42:14 Lang & Schwarz
Neuigkeiten
02.05.24 · Accesswire  |
24.04.24 · Accesswire |
05.04.24 · Accesswire |
27.03.24 · Accesswire |
26.03.24 · Accesswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,100 | +37,17 | |
| 0,7400 | +36,63 | |
| 4,7700 | +33,61 | |
| 3,5100 | +27,64 | |
| 11,505 | +21,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5100 | -29,44 | |
| 2,5900 | -32,11 | |
| 8,0900 | -35,79 | |
| 2,4100 | -51,51 | |
| 0,5744 | -57,13 |
Beitrag zu dieser Diskussion schreiben
Feedback
bedeutet erstmal rote Kurse
neue praesentation auf der webseite.
3.34 M warrants zu 37.5 und 1.95 M warrants zu 0.30 wurden die letzten Monate umgesetzt; bedeutet 1.9 M plus die 1.4 M von dem PP im Januar. Also insgesamt 3.3 M
3.34 M warrants zu 37.5 und 1.95 M warrants zu 0.30 wurden die letzten Monate umgesetzt; bedeutet 1.9 M plus die 1.4 M von dem PP im Januar. Also insgesamt 3.3 M
als ich vor 5 Jahren zum ersten Mal von Theralase gelesen habe, konnte ich auch nicht glauben, dass eine kleine Firma solche Resultate hervorbringen kann, damals war es ja nur in Tieren....heute wissen wir ja dass die gleichen Ergebnisse in Menschen erreicht werden.
also fragte ich mich, wieso Theralase die ganzen Big Pharma so extrem abhaengen kann...ich war erstmal extrem skeptisch!
nun ist es klar, dass sie das Potential von PDC's einfach uebersehen haben und sich nur auf Immunotherapien konzentriert haben. Wir wissen alle wie extrem erfolglos die bis jetzt dabei sind....Milliarden investiert und nicht wirklich viel rausgekommen!
Ist eine wahre Freude zu sehen wie diese kleine Firma Big Pharma den Stinkefinger zeigt und Resultate hervorbringt die seines gleichen sucht :-)
also fragte ich mich, wieso Theralase die ganzen Big Pharma so extrem abhaengen kann...ich war erstmal extrem skeptisch!
nun ist es klar, dass sie das Potential von PDC's einfach uebersehen haben und sich nur auf Immunotherapien konzentriert haben. Wir wissen alle wie extrem erfolglos die bis jetzt dabei sind....Milliarden investiert und nicht wirklich viel rausgekommen!
Ist eine wahre Freude zu sehen wie diese kleine Firma Big Pharma den Stinkefinger zeigt und Resultate hervorbringt die seines gleichen sucht :-)
Antwort auf Beitrag Nr.: 60.209.283 von lonade am 27.03.19 14:52:191 July 2019
A new platform technology
RuVaCare, an extracorporeal anti-cancer vaccine is efficient in breaking immune barrier to target cancer cells
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada)
A stronger anti-tumour immune response is essential to overcome the immune suppressive mechanisms adopted by cancers. We have evaluated a whole cell vaccine with extracorporeal Rutherrin-PDT treated cancer cells (RuVaCareTM) to break the suppressive barrier in an aggressive RG2-glioblastoma model. RuVaCare induced immunogenic cell death (ICD), induced immunostimulatory cytokines (IFNa, IL-1b, GMCSF), increased the survival of vaccinated rats and induced CD8+T cell responses. RuVaCare may simultaneously target multiple tumor antigens to activate the T-cell mediated immune response to fight cancer and/or prevent the recurrence of the disease, which is of highest clinical value and scientific interest.
Das finde ich ja auch ganz spannend, geht ja auch in Richtung Immuntherapie. Ich wiederhole mich, aber: Einfach verrückt
Gruß, greenhorn
A new platform technology
RuVaCare, an extracorporeal anti-cancer vaccine is efficient in breaking immune barrier to target cancer cells
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada)
A stronger anti-tumour immune response is essential to overcome the immune suppressive mechanisms adopted by cancers. We have evaluated a whole cell vaccine with extracorporeal Rutherrin-PDT treated cancer cells (RuVaCareTM) to break the suppressive barrier in an aggressive RG2-glioblastoma model. RuVaCare induced immunogenic cell death (ICD), induced immunostimulatory cytokines (IFNa, IL-1b, GMCSF), increased the survival of vaccinated rats and induced CD8+T cell responses. RuVaCare may simultaneously target multiple tumor antigens to activate the T-cell mediated immune response to fight cancer and/or prevent the recurrence of the disease, which is of highest clinical value and scientific interest.
Das finde ich ja auch ganz spannend, geht ja auch in Richtung Immuntherapie. Ich wiederhole mich, aber: Einfach verrückt
Gruß, greenhorn
Noch ein paar Details zum Kongress, Theralase wird dort omnipraesent sein...
Es gibt Vortraege zur Dosimetrie mit anwendungsspezifischem Supercomputing für Blasenkrebs und einem personalisierten Krebsimpfstoff, der das körpereigene Immunsystem für praktisch alle Krebsarten stimuliert.
Theralase verbindet also die extrem erfolgreiche PDT Tech mit Immunotherapien! Die schaffen was Big Pharma bis jetzt vergeblich versucht....
17th International Photodynamic Association World Congress
There will be six Theralase related presentations, including one on Theralase's anti cancer vaccine RuVaCare, one on peripheral lung cancer and one on rutherrin use against GBM.
17th International Photodynamic Association World Congress
Boston Marriott Cambridge
Cambridge, Massachusetts, United States
Friday - Thursday 28 June - 4 July 2019
30 June 2019
Efficacy of ruthenium coordination complex based Rutherrin in a pre-clinical rat glioblastoma (GBM) model
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada); Carl Fisher, Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada)
The efficacy of Rutherrin based on the Photosensitizer TLD1433 was evaluated in the RG2 preclinical glioma model in vitro and in vivo. The in vitro LD50 as a function of photons absorbed by the photosensitizer was lower than for ALA-induced PpIX using previously published protocols. In vivo Rutherrin demonstrated a higher specific uptake ratio, longer survival times, lower edema and a higher infiltration of CD8+T immune-regulating cells and the in vivo threshold (number of photons absorbed to cause cell death) is two orders of magnitude lower compared to ALA-induced PpIX treated animals.
3 July 2019
Dosimetry recommendations for NMIBC: a simulation and in vivo study
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Daniel Molehuis, Univ. of Toronto (Canada); Angelica Manalac, McMaster Univ. (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Wayne Embree, Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada); Girish Kulkani, Michael Jewett, Univ. Health Network (Canada)
Optimizing and monitoring the irradiance of a bladder wall was investigated through numerical simulations of 6 anatomical bladders as a function of the average tissue optical properties. To quantify the average bladder wall irradiance, multiple sensors are required to become independent of the bladder shape. Nevertheless, the sensor’s responsivity to any given irradiance at the bladder wall remains slightly dependent on the tissue optical properties as well as those of the bladder void if the latter cannot be kept transparent. The experimentally measured irradiances ranges in each bladder matched those predicted by the simulations for the first six patients in a clinical trial of TLD1433 mediated Photodynamic Therapy.
30 June 2019
TLD-1433 photodynamic therapy for BCG-unresponsive NMIBC: a Phase IB clinical study (Invited Paper)
Author(s): Lothar D. Lilge, Univ. Health Network (Canada), Univ. of Toronto (Canada); Girish Kulkani, Univ. of Toronto (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase, Inc. (Canada); Nathan Perlis, Michael Nesbitt, Univ. Health Network (Canada); Roger White , Wayne Embree , Theralase, Inc. (Canada); Michael Jewett , Univ. of Toronto (Canada)
TDL1433 mediated PDT for NMIBC for patients who failed standard BCG immunotherapy was shown to be safe and well tolerated at the therapeutic dose. Contributing to the safety of the treatment is instilling the PS to minimize pharmacokinetic influences on the drug dose, and monitoring the irradiance on the bladder wall to minimize optical effects when illuminating a cavity with unknown optical properties. Light source limitations resulted in long irradiation times, and higher total power fiber optical delivery must be attained for clinical translation. The exploratory efficacy data is encouraging.
1 July 2019
A new platform technology RuVaCare, an extracorporeal anti-cancer vaccine is efficient in breaking immune barrier to target cancer cells
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada)
A stronger anti-tumour immune response is essential to overcome the immune suppressive mechanisms adopted by cancers. We have evaluated a whole cell vaccine with extracorporeal Rutherrin®-PDT treated cancer cells (RuVaCareTM) to break the suppressive barrier in an aggressive RG2-glioblastoma model. RuVaCare™ induced immunogenic cell death (ICD), induced immunostimulatory cytokines (IFNa, IL-1b, GMCSF), increased the survival of vaccinated rats and induced CD8+T cell responses. RuVaCare ™ may simultaneously target multiple tumor antigens to activate the T-cell mediated immune response to fight cancer and/or prevent the recurrence of the disease, which is of highest clinical value and scientific interest.
3 July 2019
Modelling novel PDT approaches to target peripheral lung cancers
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Christopher McFadden, Univ. of Toronto (Canada); Khaled Ramadan, Univ. Health Network (Canada); Zhangcheng Zheng, Univ. of Toronto (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Marcelo Cypel, Univ. Health Network (Canada)
In silico simulations highlight the ability and limitations to target peripheral lung tumours either as an index lesion or as diffuse disease throughout one lobe. Using estimated PDT tissue Threshold values from literature and measured tissue optical properties the simulations provide required photosensitizer selective uptake ratios to achieve more than 98% tumour destruction at the established clinically acceptable extent of normal lung tissue damage. Hence, using this tool, the oncological surgeon can evaluate for each patient if and how transbronchial PDT can be a promising treatment modality.
30 June 2019
Photobiomodulation inhibits Warburg metabolism and potentiates a dose dependent response by glioblastoma cells to ruthenium-based photodynamic therapy
Author(s): Mark Roufaiel, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada); Lothar D. Lilge, Univ. of Toronto (Canada), Univ. Health Network (Canada)
Cancer cells reprogram their metabolism to promote tumorigenesis and increase drug resistance, through the Warburg Effect. The impact of PBM on the Warburg Effect and antineoplastic treatment such as PDT in glioblastoma cells was investigated. Dose dependent PBM mediated decreased glycolysis, increased oxidative phosphorylation, altered cellular proliferation rate, and induced a biphasic response in mRNA expression of multiple cancer genetic markers. These changes are reflected in the efficacy of antineoplastic therapies, here TLD1433-mediated PDT, whereby the efficacy changes also showed a biphasic response, which was not affected by CCO and ROS inhibition, suggesting a CCO and ROS independent mechanism.
Also - Two Presentations by Dr. McFarland at Conference
30 June 2019
Design and development of metal complex photosensitizers for photodynamic therapy (Invited Paper)
Author(s): Sherri McFarland, The Univ. of North Carolina at Greensboro (United States)
Transition metal complexes are of interest for their use as photosensitizers (PSs) in light-based applications, including photodynamic therapy (PDT). Certain coordination complexes of ruthenium (Ru) yield potent PDT effects in a variety of in vitro and in vivo cancer models. One example is our own TLD1433, which is the first Ru PS to enter (and successfully complete) a human clinical trial for treating cancer with PDT. The design and development of transition metal complexes for PDT will be discussed.
30 June 2019
Novel metal-based photosensitizers for photodynamic therapy: exploratory study
Author(s): Lindsey Carlsen, Taylor Mandeville, Roswell Park Comprehensive Cancer Ctr. (United States); Patrick Barrett, Evan Bradner, Tariq Sainuddin, Sherri McFarland, The Univ. of North Carolina at Greensboro (United States); Sarah Chamberlain, David Bellnier, Gal Shafirstein, Roswell Park Comprehensive Cancer Ctr. (United States)
We investigated the efficacy of Ruthenium and Osmium-based coordination complexes as potential photosensitizers (PS’s) for photodynamic therapy (PDT). These compounds act as an alternative to porphyrin-based PS’s, and are capable of activation over a broad range of wavelengths. Compounds were tested at 532 nm and 630 nm wavelengths in-vitro, using metastatic murine melanoma (B16F10), murine squamous cell carcinoma (SCCVII), and human adenocarcinoma (A549) cell lines. Results revealed effective PDT-mediated cytotoxicity in all three cell lines, with minimal dark toxicity observed. These novel PS’s are anticipated to be effective against multiple cancers.
Es gibt Vortraege zur Dosimetrie mit anwendungsspezifischem Supercomputing für Blasenkrebs und einem personalisierten Krebsimpfstoff, der das körpereigene Immunsystem für praktisch alle Krebsarten stimuliert.
Theralase verbindet also die extrem erfolgreiche PDT Tech mit Immunotherapien! Die schaffen was Big Pharma bis jetzt vergeblich versucht....
17th International Photodynamic Association World Congress
There will be six Theralase related presentations, including one on Theralase's anti cancer vaccine RuVaCare, one on peripheral lung cancer and one on rutherrin use against GBM.
17th International Photodynamic Association World Congress
Boston Marriott Cambridge
Cambridge, Massachusetts, United States
Friday - Thursday 28 June - 4 July 2019
30 June 2019
Efficacy of ruthenium coordination complex based Rutherrin in a pre-clinical rat glioblastoma (GBM) model
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada); Carl Fisher, Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada)
The efficacy of Rutherrin based on the Photosensitizer TLD1433 was evaluated in the RG2 preclinical glioma model in vitro and in vivo. The in vitro LD50 as a function of photons absorbed by the photosensitizer was lower than for ALA-induced PpIX using previously published protocols. In vivo Rutherrin demonstrated a higher specific uptake ratio, longer survival times, lower edema and a higher infiltration of CD8+T immune-regulating cells and the in vivo threshold (number of photons absorbed to cause cell death) is two orders of magnitude lower compared to ALA-induced PpIX treated animals.
3 July 2019
Dosimetry recommendations for NMIBC: a simulation and in vivo study
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Daniel Molehuis, Univ. of Toronto (Canada); Angelica Manalac, McMaster Univ. (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Wayne Embree, Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada); Girish Kulkani, Michael Jewett, Univ. Health Network (Canada)
Optimizing and monitoring the irradiance of a bladder wall was investigated through numerical simulations of 6 anatomical bladders as a function of the average tissue optical properties. To quantify the average bladder wall irradiance, multiple sensors are required to become independent of the bladder shape. Nevertheless, the sensor’s responsivity to any given irradiance at the bladder wall remains slightly dependent on the tissue optical properties as well as those of the bladder void if the latter cannot be kept transparent. The experimentally measured irradiances ranges in each bladder matched those predicted by the simulations for the first six patients in a clinical trial of TLD1433 mediated Photodynamic Therapy.
30 June 2019
TLD-1433 photodynamic therapy for BCG-unresponsive NMIBC: a Phase IB clinical study (Invited Paper)
Author(s): Lothar D. Lilge, Univ. Health Network (Canada), Univ. of Toronto (Canada); Girish Kulkani, Univ. of Toronto (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase, Inc. (Canada); Nathan Perlis, Michael Nesbitt, Univ. Health Network (Canada); Roger White , Wayne Embree , Theralase, Inc. (Canada); Michael Jewett , Univ. of Toronto (Canada)
TDL1433 mediated PDT for NMIBC for patients who failed standard BCG immunotherapy was shown to be safe and well tolerated at the therapeutic dose. Contributing to the safety of the treatment is instilling the PS to minimize pharmacokinetic influences on the drug dose, and monitoring the irradiance on the bladder wall to minimize optical effects when illuminating a cavity with unknown optical properties. Light source limitations resulted in long irradiation times, and higher total power fiber optical delivery must be attained for clinical translation. The exploratory efficacy data is encouraging.
1 July 2019
A new platform technology RuVaCare, an extracorporeal anti-cancer vaccine is efficient in breaking immune barrier to target cancer cells
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada)
A stronger anti-tumour immune response is essential to overcome the immune suppressive mechanisms adopted by cancers. We have evaluated a whole cell vaccine with extracorporeal Rutherrin®-PDT treated cancer cells (RuVaCareTM) to break the suppressive barrier in an aggressive RG2-glioblastoma model. RuVaCare™ induced immunogenic cell death (ICD), induced immunostimulatory cytokines (IFNa, IL-1b, GMCSF), increased the survival of vaccinated rats and induced CD8+T cell responses. RuVaCare ™ may simultaneously target multiple tumor antigens to activate the T-cell mediated immune response to fight cancer and/or prevent the recurrence of the disease, which is of highest clinical value and scientific interest.
3 July 2019
Modelling novel PDT approaches to target peripheral lung cancers
Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Christopher McFadden, Univ. of Toronto (Canada); Khaled Ramadan, Univ. Health Network (Canada); Zhangcheng Zheng, Univ. of Toronto (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Marcelo Cypel, Univ. Health Network (Canada)
In silico simulations highlight the ability and limitations to target peripheral lung tumours either as an index lesion or as diffuse disease throughout one lobe. Using estimated PDT tissue Threshold values from literature and measured tissue optical properties the simulations provide required photosensitizer selective uptake ratios to achieve more than 98% tumour destruction at the established clinically acceptable extent of normal lung tissue damage. Hence, using this tool, the oncological surgeon can evaluate for each patient if and how transbronchial PDT can be a promising treatment modality.
30 June 2019
Photobiomodulation inhibits Warburg metabolism and potentiates a dose dependent response by glioblastoma cells to ruthenium-based photodynamic therapy
Author(s): Mark Roufaiel, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada); Lothar D. Lilge, Univ. of Toronto (Canada), Univ. Health Network (Canada)
Cancer cells reprogram their metabolism to promote tumorigenesis and increase drug resistance, through the Warburg Effect. The impact of PBM on the Warburg Effect and antineoplastic treatment such as PDT in glioblastoma cells was investigated. Dose dependent PBM mediated decreased glycolysis, increased oxidative phosphorylation, altered cellular proliferation rate, and induced a biphasic response in mRNA expression of multiple cancer genetic markers. These changes are reflected in the efficacy of antineoplastic therapies, here TLD1433-mediated PDT, whereby the efficacy changes also showed a biphasic response, which was not affected by CCO and ROS inhibition, suggesting a CCO and ROS independent mechanism.
Also - Two Presentations by Dr. McFarland at Conference
30 June 2019
Design and development of metal complex photosensitizers for photodynamic therapy (Invited Paper)
Author(s): Sherri McFarland, The Univ. of North Carolina at Greensboro (United States)
Transition metal complexes are of interest for their use as photosensitizers (PSs) in light-based applications, including photodynamic therapy (PDT). Certain coordination complexes of ruthenium (Ru) yield potent PDT effects in a variety of in vitro and in vivo cancer models. One example is our own TLD1433, which is the first Ru PS to enter (and successfully complete) a human clinical trial for treating cancer with PDT. The design and development of transition metal complexes for PDT will be discussed.
30 June 2019
Novel metal-based photosensitizers for photodynamic therapy: exploratory study
Author(s): Lindsey Carlsen, Taylor Mandeville, Roswell Park Comprehensive Cancer Ctr. (United States); Patrick Barrett, Evan Bradner, Tariq Sainuddin, Sherri McFarland, The Univ. of North Carolina at Greensboro (United States); Sarah Chamberlain, David Bellnier, Gal Shafirstein, Roswell Park Comprehensive Cancer Ctr. (United States)
We investigated the efficacy of Ruthenium and Osmium-based coordination complexes as potential photosensitizers (PS’s) for photodynamic therapy (PDT). These compounds act as an alternative to porphyrin-based PS’s, and are capable of activation over a broad range of wavelengths. Compounds were tested at 532 nm and 630 nm wavelengths in-vitro, using metastatic murine melanoma (B16F10), murine squamous cell carcinoma (SCCVII), and human adenocarcinoma (A549) cell lines. Results revealed effective PDT-mediated cytotoxicity in all three cell lines, with minimal dark toxicity observed. These novel PS’s are anticipated to be effective against multiple cancers.
Trading Spotlight
Der Kongress könnte eine feine Sache werden, Dr. Sherri McFarland ist auch da...
https://spie.org/profile/Sherri.McFarland-4169619
Gruß, greenhorn
https://spie.org/profile/Sherri.McFarland-4169619
Gruß, greenhorn
Antwort auf Beitrag Nr.: 60.199.578 von greenhorn1998 am 26.03.19 16:35:19Vielleicht brauchen die in Can etwas länger zum Lesen und Verstehen. Erst kürzlich hochgezogen mit fast 10% und jetzt Bröckelkurs
Antwort auf Beitrag Nr.: 60.198.966 von Wolfirainbow am 26.03.19 15:45:31Fein, fein
Hier noch mal der Link zur News - Phase 2 soll in Q2 in Kanada starten. Das fängt am 1. April an
http://business.itbusinessnet.com/2019/03/theralases-phase-i…
Gruß, greenhorn
Hier noch mal der Link zur News - Phase 2 soll in Q2 in Kanada starten. Das fängt am 1. April an
http://business.itbusinessnet.com/2019/03/theralases-phase-i…
Gruß, greenhorn
TORONTO, ON / ACCESSWIRE / MARCH 26, 2019 /Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association ("IPA") World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019.
IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy ("PDT") and PhotoDiagnosis ("PD") since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field.
This year, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, an esteemed PDT expert and a member of the Medical and Scientific Advisory Board ("MSAB"), was elected to be a Co-Chairman of the Urology Session at the Congress and has been invited to deliver a presentation entitled, "Improving the Safety and Efficacy of PhotoDynamic Therapy of Bladder Cancer – Light Dosimetry Aspects of a Phase Ib Study Using Intravesical TLD-1433 (a Ruthenium (II)-Based Photosensitizer) in Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients". Dr. Lilge's presentation will focus on the laser dosimetry utilized and clinical outcomes of the Study. In addition, Dr. Lilge will discuss applications of Theralase's Anti-Cancer Technology ("ACT") to other cancers, as well as the potential for a combination of Theralase's lead PDC, TLD-1433, with various physical therapeutic modalities.
IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy ("PDT") and PhotoDiagnosis ("PD") since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field.
This year, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, an esteemed PDT expert and a member of the Medical and Scientific Advisory Board ("MSAB"), was elected to be a Co-Chairman of the Urology Session at the Congress and has been invited to deliver a presentation entitled, "Improving the Safety and Efficacy of PhotoDynamic Therapy of Bladder Cancer – Light Dosimetry Aspects of a Phase Ib Study Using Intravesical TLD-1433 (a Ruthenium (II)-Based Photosensitizer) in Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients". Dr. Lilge's presentation will focus on the laser dosimetry utilized and clinical outcomes of the Study. In addition, Dr. Lilge will discuss applications of Theralase's Anti-Cancer Technology ("ACT") to other cancers, as well as the potential for a combination of Theralase's lead PDC, TLD-1433, with various physical therapeutic modalities.
Shorts runter von 1,95 Mio auf nur 205k...hingen also mit den Warrants zusammen.
Durchsuchen
